Biotechnology company Depixus has raised €30.6 million in an oversubscribed Series A financing. The funds will be used to further develop its proprietary MAGNA™ instrumentation system, workflows and reagents for commercial launch. The round was jointly led by Lansdowne Partners and the PSIM Fund managed by Bpifrance on behalf of the French government, with participation from Casdin Capital and existing investors including Arix Bioscience. This financing brings the company's total equity and grant funding to date to over €41 million ($47 million).
Depixus, based in Paris and Cambridge, which has developed a cutting-edge technology called MAGNA™ to unlock the secrets of the dynamic genome, has grown rapidly since its founding in 2012.
Jérémie Swiecznik, partner, Benoît Courtet, counsel and Maxim Khlopotin, associate, accompanied Bpifrance on this transaction.
Depixus, based in Paris and Cambridge, which has developed a cutting-edge technology called MAGNA™ to unlock the secrets of the dynamic genome, has grown rapidly since its founding in 2012.
Jérémie Swiecznik, partner, Benoît Courtet, counsel and Maxim Khlopotin, associate, accompanied Bpifrance on this transaction.